TCL1A (TCL1 family AKT coactivator A) is a serine/threonine kinase activator that enhances phosphorylation and activation of AKT proteins, promoting cell survival and proliferation 1. The protein functions as an AKT coactivator involved in intracellular signal transduction, with activity localized to multiple cellular compartments including the nucleus, cytosol, and endoplasmic reticulum. Mechanism: TCL1A expression is restricted to early B cells and is induced by mutations in genes such as TET2 and ASXL1 in hematopoietic stem cells 2. TCL1A activation mediates stem cell expansion and fitness advantages through AKT signaling pathways 2. In B cells, TCL1A promotes proliferation and enhances trogocytosis on dendritic cells by upregulating CR2, improving antigen presentation 3. Disease Relevance: TCL1A overexpression is a defining pathogenic driver in T-cell prolymphocytic leukemia (T-PLL), typically occurring with ATM loss 4. TCL1A also cooperates with RANK signaling to induce B-cell malignancies including chr14 lymphocytic leukemia and multiple myeloma 5. A germline polymorphism in the TCL1A promoter associates with reduced clonal expansion rates in common driver mutations 26. Clinical Significance: TCL1A expression in tertiary lymphoid structures predicts favorable prognosis in oral squamous cell carcinoma and cholangiocarcinoma 37, suggesting TCL1A-expressing B cells support anti-tumor immunity and may represent a novel immunotherapy target.